Anti-TNFSF9 / 4-1BBL Reference Antibody (Abbvie patent anti-TNFSF9)
Recombinant Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| FC, E, FTA |
---|---|
Primary Accession | P41273 |
Reactivity | Cynomolgus, Human |
Clonality | Monoclonal |
Isotype | IgG1 |
Calculated MW | 150 KDa |
Target/Specificity | TNFSF9 / 4-1BBL |
---|---|
Endotoxin | < 0.001EU/ µg,determined by LAL method. |
Conjugation | Unconjugated |
Expression system | CHO Cell |
Format | Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column. |
Name | TNFSF9 |
---|---|
Function | Cytokine that binds to TNFRSF9. Induces the proliferation of activated peripheral blood T-cells. May have a role in activation- induced cell death (AICD). May play a role in cognate interactions between T-cells and B-cells/macrophages. |
Cellular Location | Membrane; Single-pass type II membrane protein. |
Tissue Location | Expressed in brain, placenta, lung, skeletal muscle and kidney |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.